WO2002095022A3 - Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences - Google Patents

Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences Download PDF

Info

Publication number
WO2002095022A3
WO2002095022A3 PCT/EP2002/006580 EP0206580W WO02095022A3 WO 2002095022 A3 WO2002095022 A3 WO 2002095022A3 EP 0206580 W EP0206580 W EP 0206580W WO 02095022 A3 WO02095022 A3 WO 02095022A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding
dna
sub
amino acid
acid residues
Prior art date
Application number
PCT/EP2002/006580
Other languages
French (fr)
Other versions
WO2002095022A2 (en
Inventor
Ulrich K Laemmli
Samuel Janssen
Original Assignee
Univ Geneve
Ulrich K Laemmli
Samuel Janssen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Geneve, Ulrich K Laemmli, Samuel Janssen filed Critical Univ Geneve
Priority to AU2002310764A priority Critical patent/AU2002310764A1/en
Publication of WO2002095022A2 publication Critical patent/WO2002095022A2/en
Publication of WO2002095022A3 publication Critical patent/WO2002095022A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers

Abstract

The present invention relates to small organic molecules comprising at least one DNA-binding unit capable of sequence specific binding to the minor groove of a DNA molecule comprising the sequence 5'-GGG-3', said compound comprising covalently-linked first and second DNA-binding sub-units, each sub-unit comprising heterocyclic amino acid residues, the amino acid residues of the first sub-unit forming binding pairs with a portion of the amino acid residues of the second sub-unit, thereby providing a paired DNA-binding portion and an adjacent unpaired DNA-binding portion, wherein the paired portion and the unpaired portion together provide at least three consecutive amino acid residues preferentially binding to G, the paired portion providing no more than two consecutive residues preferentially binding to G. The invention also relates to the use of these compounds in targeting specific sequences, particularly telomeres, in vivo, in vitro and ex vivo.
PCT/EP2002/006580 2001-05-21 2002-05-21 Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences WO2002095022A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002310764A AU2002310764A1 (en) 2001-05-21 2002-05-21 Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29242001P 2001-05-21 2001-05-21
US60/292,420 2001-05-21

Publications (2)

Publication Number Publication Date
WO2002095022A2 WO2002095022A2 (en) 2002-11-28
WO2002095022A3 true WO2002095022A3 (en) 2003-11-20

Family

ID=23124591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006580 WO2002095022A2 (en) 2001-05-21 2002-05-21 Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences

Country Status (2)

Country Link
AU (1) AU2002310764A1 (en)
WO (1) WO2002095022A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032594A2 (en) * 2003-10-03 2005-04-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alkylators linked to polyamides as dna binding agents
GB0619325D0 (en) 2006-09-30 2006-11-08 Univ Strathclyde New compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049142A1 (en) * 1997-04-06 1998-11-05 California Institute Of Technology Dna-binding pyrrole and imidazole polyamide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998049142A1 (en) * 1997-04-06 1998-11-05 California Institute Of Technology Dna-binding pyrrole and imidazole polyamide derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUSANNE E. SWALLEY ET AL.: "Discrimination of 5'-GGGG-3', 5'-GCGC-3', and 5'-GGCC-3' sequences in the minor groove of DNA by eight-ring hairpin polyamides", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 119, no. 30, - 30 July 1997 (1997-07-30), AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US, pages 6953 - 6961, XP002231562, ISSN: 0002-7863 *
SWALLEY S E ET AL: "RECOGNITION OF A 5'-(A,T)GGG(A,T)2-3' SEQUENCE IN THE MINOR GROOVE OF DNA BY AN EIGHT-RING HAIRPIN POLYAMIDE", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 118, no. 35, 4 September 1996 (1996-09-04), pages 8198 - 8206, XP002066377, ISSN: 0002-7863 *

Also Published As

Publication number Publication date
WO2002095022A2 (en) 2002-11-28
AU2002310764A1 (en) 2002-12-03

Similar Documents

Publication Publication Date Title
WO2004024757A3 (en) Modified pna molecules
WO2006131928A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
BR9913532A (en) New heteroaromatic inhibitors of fructose 1,6-bisphosphatase
WO2003020949A3 (en) Targeted nucleic acid constructs and uses related thereto
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2005067644A3 (en) Conjugated small molecules
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2001066553A3 (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
WO2002014485A3 (en) Kallikrein gene
WO2006054297A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO1999024452A3 (en) Pyrimidine derivatives for labeled binding partners
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
HK1052461A1 (en) Pharmaceutical composition comprising pemetrexed together with monothioglycerol, l-cystein or thioglycolic acid.
MXPA03006984A (en) Nucleotide sequence mediating male fertility and method of using same.
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2003050283A3 (en) A structure for presenting desired peptide sequences
WO2003029422A3 (en) Noonan syndrome gene
WO2001068804A8 (en) Nucleic acid sequences associated with aging, particularly skin aging
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
WO2002006315A3 (en) Novel nucleic acid and amino acid sequences
WO2002095022A3 (en) Sequence-specific dna binding compounds and their use in targeting telomeres and other dna sequences

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1)EPCT:EPO FORM 1205A DATED 09.03.2004

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP